Logo

Roche Receives FDA's Emergency Use Authorization for its Elecsys to Detect COVID-19

Share this

Roche Receives FDA's Emergency Use Authorization for its Elecsys to Detect COVID-19

Shots:

  • Roche has received the US FDA’s EUA for its Elecsys anti-SARS-CoV-2 Ab test to detect patient’s immune response to the COVID-19 and run on its cobas e analysers- delivering results in ~18 minutes- up to 300 tests/hour
  • Elecsys Anti-SARS-CoV-2 serology test- an immunoassay used an in-solution double-antigen sandwich format in 5272 patient blood samples with COVID-19 and patient developed Abs against COVID-19 to detect Abs with >99.8% specificity and 100% sensitivity in samples taken 14 days post-PCR confirmation
  • Roche will ramp-up production capacity to high double-digit millions of tests/months in May for countries accepting the CE mark and in the US- under EUA

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions